Qiagen NV launched its ipsogen JAK2 RGQ PCR kit in the U.S.

The test was cleared by the U.S. FDA for the detection of the JAK2 V617F/G1849T allele in genomic DNA extracted from ethylenediaminetetraacetic acid whole blood.

QIAGEN's ipsogen is the first and only FDA-cleared qualitative in vitro diagnostic test for the JAK2 V617F mutation, which is important for the diagnosis of Polycythemia Vera.

Janus kinase 2 or JAK2 V617F is an acquired, somatic mutation present in the majority of patients with myeloproliferative cancer i.e. nearly 100% of patients with polycythemia vera and in about 50% of patients with essential thrombocytosis and primary myelofibrosis.